Proton Pump Inhibitors in the Management of GERD

被引:29
作者
Katz, Philip O. [1 ]
Zavala, Stacey [1 ]
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Albert Einstein Med Ctr, Philadelphia, PA 19107 USA
关键词
Proton pump inhibitors; GERD; Pharmacologic properties; GASTROESOPHAGEAL-REFLUX DISEASE; NOCTURNAL GASTRIC-ACIDITY; ESOMEPRAZOLE; 40; MG; EROSIVE ESOPHAGITIS; ORAL SUSPENSION; OMEPRAZOLE; RISK; BREAKTHROUGH; THERAPY; ARTICLE;
D O I
10.1007/s11605-009-1015-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief. Results and Discussion Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are "refractory" to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for "failure," is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy. Conclusion Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.
引用
收藏
页码:62 / 66
页数:5
相关论文
共 29 条
[1]   APPROPRIATE ACID SUPPRESSION FOR THE MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE [J].
BELL, NJV ;
BURGET, D ;
HOWDEN, CW ;
WILKINSON, J ;
HUNT, RH .
DIGESTION, 1992, 51 :59-67
[2]  
BENSANCON M, 1997, J BIOL CHEM, V272, P22438
[3]   Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease [J].
Castell, D ;
Bagin, R ;
Goldlust, B ;
Major, J ;
Hepburn, B .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (12) :1467-1474
[4]  
Castell DO, 2002, AM J GASTROENTEROL, V97, P575
[5]   Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease [J].
Dial, S ;
Delaney, JAC ;
Barkun, AN ;
Suissa, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (23) :2989-2995
[6]   Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors:: cohort and case-control studies [J].
Dial, S ;
Alrasadi, K ;
Manoukian, C ;
Huang, A ;
Menzies, D .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (01) :33-38
[7]   Extraesophageal gastroesophageal reflux disease - Presentations and approach to treatment [J].
Fennerty, MB .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1999, 28 (04) :861-+
[8]   Proton pump inhibitors: better acid suppression when taken before a meal than without a meal [J].
Hatlebakk, JG ;
Katz, PO ;
Camacho-Lobato, L ;
Castell, DO .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) :1267-1272
[9]  
Hatlebakk JG, 1998, ALIMENT PHARM THERAP, V12, P1235
[10]   Vitamin B12 levels during prolonged treatment with proton pump inhibitors [J].
Howden, CW .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 30 (01) :29-33